Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor.Clinical trial results from competitors were largely underwhelming, including this week’s ...

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Eli Lilly ( LLY 0.53%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of its ...

Cantor sees Eli Lilly reaching over 85% obesity market share by 2029–2030. Orforglipron lowered A1C by 1.3%–1.6% from baseline in Phase 3 ACHIEVE-1 trial. Historic Summer Setup: 3 "Power ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, and it's probably going to succeed. Here's why. The juggernaut is picking up speed ...

Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatments. They face supply chain challenges, but both stocks show strong ...

Eli Lilly & Co. on Thursday announced the launch of new digital health services that could help smooth patient access to the obesity drug Zepbound and other medications — but also warned against ...